Home Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.2, p.158–160,2021

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.122, No.2, p.158–160,2021

Title: Association of polypharmacy and Parkinson’s disease prevalence
Author: Y. Chen, Z. Yu

Abstract: OBJECTIVE: Polypharmacy and multiple diseases are common in geriatric practice; however, such kind of multiple interventions might result in adverse effects. Some previous studies have found the association of polypharmacy and Parkinson’s disease, to confirm this relationship, we conducted a meta-analysis to analyze this issue quantitively.
MATERIALS AND METHODS: In total, we included 8 studies, 165,689 polypharmacy subjects and 373,660 non-polypharmacy controls, and 5644 PD patients among these subjects and controls.
RESULTS: For model without any adjustment, polypharmacy group has a significantly higher prevalence than control, OR = 2.53, 95 %CI [2.00, 3.20] (p < 0.001). However, this model showed a very high heterogeneity (I2 = 91 %, p < 0.001). In age, gender and disease history adjusted model, polypharmacy group has a significantly higher prevalence than control, OR = 1.43, 95 %CI [1.35, 1.52], p < 0.001. The heterogeneity decreased to zero (I2 = 0 %, p < 0.45).
CONCLUSION: In this study we have found an association between PD risk and polypharmacy, a better designed prospective long-term cohort study might be required for further discussion on this issue (Tab. 1, Fig. 5, Ref. 14).

Keywords: polypharmacy, PD, Parkinson, meta-analysis
Published online: 26-Jan-2021
Year: 2021, Volume: 122, Issue: 2 Page From: 158, Page To: 160
doi:10.4149/BLL_2021_024


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.